Last updated: May 04, 2026

Application No. 18/285,996

ANTI-CD73 ANTIBODIES

Non-Final OA

Filed

Oct 06, 2023

Priority

Apr 09, 2021 — GB 2105110.7 +1 more

Examiner

OUSPENSKI, ILIA I

Art Unit

1644

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Cancer Research Technology Limited

OA Round

1 (Non-Final)

Interview Optional

— +20.4% interview lift. Examiner has a relatively high allowance rate (78%); +20.4% interview lift. A written response may suffice.

Based on 1100 resolved cases, 2023–2026

Examiner Intelligence

OUSPENSKI, ILIA I View full profile →

Grants 78% — above average

Career Allowance Rate

853 granted / 1100 resolved

+17.5% vs TC avg

Strong +20% interview lift

Without

With

+20.4%

Interview Lift

resolved cases with interview

Typical timeline

2y 7m

Avg Prosecution

45 currently pending

Career history

1145

Total Applications

across all art units

Statute-Specific Performance

§101

1.7%

-38.3% vs TC avg

§103

10.6%

-29.4% vs TC avg

§102

19.2%

-20.8% vs TC avg

§112

17.2%

-22.8% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1100 resolved cases

Prosecution Timeline

Oct 06, 2023

Application Filed

Mar 19, 2026

Non-Final Rejection (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/285,184

Patent 12600776

ANTI-L1CAM ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME

3y 12m to grant Granted Apr 14, 2026

17/523,702

Patent 12590153

TREATMENT OF PD-L1-NEGATIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY

4y 4m to grant Granted Mar 31, 2026

19/193,652

Patent 12590154

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

11m to grant Granted Mar 31, 2026

17/831,637

Patent 12583903

CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF

3y 9m to grant Granted Mar 24, 2026

17/932,822

Patent 12583934

ANTI-CD26 ANTIBODIES AND USES THEREOF

3y 6m to grant Granted Mar 24, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

78%

Grant Probability

98%

With Interview (+20.4%)

2y 7m (~0m remaining)

Median Time to Grant

Low

PTA Risk

Based on 1100 resolved cases by this examiner. Grant probability derived from career allowance rate.